Pfizzer are gaining exposure to antisense gen2 by taking out one of ISIS’s smaller partners... it opens pandoras box as to the driver behind ANPs share price lately.
Also shows that with GlaxoSmithKline in bed with ISIS... the others maybe of the view that if they can’t get then they will just take!!
Which makes ANP look even more like a sitting duck IMHO
Nov. 27. 2007-- Isis Pharmaceuticals, Inc. (Nasdaq: IISIS) and Excaliard Pharmaceuticals,Inc. announced today a new collaboration to discover and develop antisensedrugs for the local treatment of fibrotic diseases. Executive Vice President and CFO of Isis. "Excaliard will benefit from access to our technology and intellectual property and join a growing list of partners who have focused teams dedicated to advancing antisense drugs and who enable us to continue to expand the breadth of our antisense drug pipeline."
“January 10th, 2011 Excaliard Pharmaceuticals, Inc., today announced results from three Phase 2 clinical trials of EXC 001 in skin scarring. EXC 001 is an antisense oligonucleotide designed to interrupt the process of fibrosis by inhibiting expression of connective tissue growth factor (CTGF).”
“NEW YORK, N.Y., and SAN DIEGO, Calif., November 22, 2011 – Pfizer Inc.(NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis”
First GlaxoSmithKline then Pfizer both now have skin in the antisense game.
It maybe on for both young and old soon imo...
JMO, and Good Luck!
ANP Price at posting:
29.0¢ Sentiment: LT Buy Disclosure: Held
